JP2008516610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516610A5 JP2008516610A5 JP2007537026A JP2007537026A JP2008516610A5 JP 2008516610 A5 JP2008516610 A5 JP 2008516610A5 JP 2007537026 A JP2007537026 A JP 2007537026A JP 2007537026 A JP2007537026 A JP 2007537026A JP 2008516610 A5 JP2008516610 A5 JP 2008516610A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- protein
- seq
- positions
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 51
- 108020001507 fusion proteins Proteins 0.000 claims 38
- 102000037865 fusion proteins Human genes 0.000 claims 38
- 230000002163 immunogen Effects 0.000 claims 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 17
- 239000003981 vehicle Substances 0.000 claims 16
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 claims 14
- 230000028993 immune response Effects 0.000 claims 14
- 235000018102 proteins Nutrition 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 11
- 108700008783 Hepatitis C virus E1 Proteins 0.000 claims 10
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 10
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- 101710125507 Integrase/recombinase Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 101800001473 Spike glycoprotein E2 Proteins 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62015804P | 2004-10-18 | 2004-10-18 | |
| PCT/US2005/037499 WO2006044923A2 (en) | 2004-10-18 | 2005-10-18 | Yeast-based therapeutic for chronic hepatitis c infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011216827A Division JP2012034700A (ja) | 2004-10-18 | 2011-09-30 | 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516610A JP2008516610A (ja) | 2008-05-22 |
| JP2008516610A5 true JP2008516610A5 (https=) | 2008-12-04 |
Family
ID=36203669
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537026A Pending JP2008516610A (ja) | 2004-10-18 | 2005-10-18 | 酵母を用いた慢性c型肝炎感染の治療 |
| JP2011216827A Pending JP2012034700A (ja) | 2004-10-18 | 2011-09-30 | 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法 |
| JP2013162490A Withdrawn JP2014012679A (ja) | 2004-10-18 | 2013-08-05 | 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011216827A Pending JP2012034700A (ja) | 2004-10-18 | 2011-09-30 | 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法 |
| JP2013162490A Withdrawn JP2014012679A (ja) | 2004-10-18 | 2013-08-05 | 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US7632511B2 (https=) |
| EP (2) | EP2460533A3 (https=) |
| JP (3) | JP2008516610A (https=) |
| KR (1) | KR20070068460A (https=) |
| CN (2) | CN102614510A (https=) |
| AU (1) | AU2005295317B2 (https=) |
| BR (1) | BRPI0516356A (https=) |
| CA (1) | CA2584562A1 (https=) |
| IL (1) | IL182609A (https=) |
| MX (1) | MX2007004662A (https=) |
| SG (1) | SG156652A1 (https=) |
| WO (1) | WO2006044923A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| CN102370974B (zh) * | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| CN102614510A (zh) * | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| CN101355965A (zh) | 2005-06-08 | 2009-01-28 | 达纳-法伯癌症研究院 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| KR20080043775A (ko) * | 2005-07-11 | 2008-05-19 | 글로브이뮨 | 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물 |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| JP2009534428A (ja) * | 2006-04-25 | 2009-09-24 | インターツェル・アクチェンゲゼルシャフト | Hcvワクチン接種 |
| AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| CN103536915A (zh) * | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| AU2008214029B2 (en) * | 2007-02-02 | 2014-01-30 | Globelmmune, Inc. | Methods for producing yeast-based vaccines |
| EP2134358A1 (en) * | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| US7840668B1 (en) * | 2007-05-24 | 2010-11-23 | Avaya Inc. | Method and apparatus for managing communication between participants in a virtual environment |
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| EP2200638B1 (en) * | 2007-10-09 | 2016-03-16 | The University of Melbourne | Compositions for the transfection of cells |
| JP2012503011A (ja) * | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
| CA2744449C (en) * | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| KR101781966B1 (ko) | 2009-04-17 | 2017-09-27 | 글로브이뮨 | 암에 대한 병용 면역요법 조성물 및 방법 |
| AU2010291985B2 (en) * | 2009-09-14 | 2016-05-05 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| US20130121964A1 (en) * | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
| US9254320B2 (en) | 2010-12-17 | 2016-02-09 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| EA028659B1 (ru) | 2011-02-12 | 2017-12-29 | Глоубиммьюн, Инк. | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b |
| BR112013032381B1 (pt) * | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
| EP2849779B1 (en) | 2012-05-16 | 2021-01-06 | Adelaide Research & Innovation Pty Ltd. | Cellular vaccine and method of inducing an immune response in a subject |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| WO2014129412A1 (ja) | 2013-02-19 | 2014-08-28 | 国立大学法人神戸大学 | 免疫原性ポリペプチド表層発現ビフィズス菌 |
| EP2958588B1 (en) | 2013-02-22 | 2017-08-23 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| RU2718988C2 (ru) | 2013-02-22 | 2020-04-15 | Куревак Аг | Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| US10226522B2 (en) | 2013-08-30 | 2019-03-12 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| WO2015134606A1 (en) | 2014-03-05 | 2015-09-11 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
| US10799567B2 (en) * | 2014-04-11 | 2020-10-13 | Globeimmune, Inc. | Yeast-based immunotherapy and type I interferon sensitivity |
| CA2973109A1 (en) | 2015-01-09 | 2016-07-14 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
| KR102193635B1 (ko) | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
| WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3515483A4 (en) | 2016-09-21 | 2020-12-16 | The Governors of the University of Alberta | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| EP3728289B1 (en) | 2017-12-21 | 2025-09-10 | Axelia Oncology Pty Ltd | Optimised compounds |
| DE102017012109A1 (de) | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| WO2019222073A1 (en) | 2018-05-15 | 2019-11-21 | Globeimmune, Inc. | Lysates of recombinant yeast for inducing cellular immune responses |
| KR20220050873A (ko) | 2019-06-26 | 2022-04-25 | 악셀리아 온콜로지 피티와이 리미티드 | 신규한 분자 |
| EP3929295A1 (en) * | 2020-06-26 | 2021-12-29 | Universitat Pompeu Fabra | Artificial rnas for modulating rna fragments |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5523215A (en) * | 1985-03-28 | 1996-06-04 | Chiron Corporation | Enhanced purification and expression of insoluble recombinant proteins |
| US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
| US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
| US6194140B1 (en) * | 1990-04-04 | 2001-02-27 | Chiron Corporation | HCV NS3 protein fragments having helicase activity and improved solubility |
| ATE270326T1 (de) | 1990-04-04 | 2004-07-15 | Chiron Corp | Protease von hepatitis-c-virus |
| KR0181517B1 (ko) | 1990-07-09 | 1999-04-01 | 나까하라 노부유끼 | 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도 |
| US6274148B1 (en) * | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
| GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| US6190864B1 (en) | 1991-05-08 | 2001-02-20 | Chiron Corporation | HCV genomic sequences for diagnostics and therapeutics |
| WO1992022571A1 (en) | 1991-06-13 | 1992-12-23 | Baxter Diagnostics Inc. | Immunoassay for non-a non-b hepatitis |
| GB9203803D0 (en) | 1992-02-21 | 1992-04-08 | Wellcome Found | A recombinant polypeptide |
| US5413914A (en) * | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) * | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| EP0992580B1 (en) * | 1993-11-04 | 2005-03-09 | Innogenetics N.V. | Immunodominant human T-cell epitopes of Hepatitis C virus |
| US5610009A (en) * | 1994-01-28 | 1997-03-11 | Abbott Laboratories | Mammalian expression systems for hepatitis C virus envelope genes |
| BR9506059A (pt) * | 1994-07-29 | 1997-10-28 | Innogenetics Nv | Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico |
| EP1510580B1 (en) | 1994-07-29 | 2008-12-10 | Novartis Vaccines and Diagnostics, Inc. | Hepatitis C E2 truncated polypeptide and methods of obtaining the same |
| AU3241095A (en) * | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9416671D0 (en) * | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
| GB9422814D0 (en) | 1994-11-11 | 1995-01-04 | Medinnova Sf | Chemical method |
| KR100195833B1 (ko) | 1995-12-07 | 1999-06-15 | 윤종용 | 팩시밀리에서 자체진단 구현방법 |
| US5858378A (en) * | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| DE69839273T2 (de) * | 1997-01-31 | 2009-03-05 | Edward P. Chicago Cohen | Krebsimmuntherapie mit semi-allogenen zellen |
| GB9703406D0 (en) * | 1997-02-19 | 1997-04-09 | Chiron Spa | Expression of heterologous proteins |
| FR2760367B1 (fr) | 1997-03-06 | 1999-04-30 | Pasteur Merieux Serums Vacc | Composition vaccinale destinee a la prevention ou au traitement des hepatites c |
| CA2288374A1 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| NO314086B1 (no) | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
| US20050037018A1 (en) | 2003-06-20 | 2005-02-17 | Innogentics N.V. | HCV combination therapy |
| US7052696B2 (en) * | 1998-07-10 | 2006-05-30 | The United States Of America As Represented By The Department Of Health And Human Services | Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins |
| US6747135B1 (en) | 1998-10-16 | 2004-06-08 | The Board Of Trustees For The Leland Stanford Junior University | Fluorescent dye binding peptides |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| CA2389206C (en) | 1999-10-27 | 2011-01-04 | Chiron Corporation | Activation of hcv-specific t cells |
| EP1239876B1 (en) * | 1999-11-19 | 2008-07-30 | Csl Limited | Hcv vaccine compositions |
| US20050074465A1 (en) * | 1999-11-24 | 2005-04-07 | Michael Houghton | HCV fusion proteins with modified NS3 domains |
| US6986892B1 (en) * | 1999-11-24 | 2006-01-17 | Chiron Corporation | Immunogenic Hepatitis C virus non-structural polypeptides |
| CA2390082C (en) * | 1999-11-24 | 2010-06-29 | Chiron Corporation | Novel hcv non-structural polypeptide |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| GB0031430D0 (en) * | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
| PE20020908A1 (es) * | 2001-03-21 | 2002-10-26 | Cell Therapeutics Inc | Produccion recombinante de polimeros polianionicos y uso de de los mismos |
| CA2443740A1 (en) * | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| KR20040076869A (ko) * | 2001-12-18 | 2004-09-03 | 인노제네틱스 엔. 브이. | 진단적 및 치료적 용도를 위한 정제된 c형 간염 바이러스외피 단백질 |
| US20040126395A1 (en) * | 2001-12-18 | 2004-07-01 | Geert Maertens | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| US20040009937A1 (en) | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| CA2491508A1 (en) * | 2002-07-02 | 2004-01-15 | Chiron Corporation | Hcv fusion proteins with modified ns3 domains |
| ATE410693T1 (de) * | 2002-09-09 | 2008-10-15 | Novartis Vaccines & Diagnostic | Hcv-test |
| US20040138204A1 (en) * | 2002-10-30 | 2004-07-15 | Harrington James Frederick | Compositions and methods for pain reduction |
| JP2006516955A (ja) * | 2002-11-08 | 2006-07-13 | イノジェネティックス・ナムローゼ・フェンノートシャップ | E1ペプチド及びns3ペプチドを含むhcvワクチン組成物 |
| GB0226722D0 (en) * | 2002-11-15 | 2002-12-24 | Glaxo Group Ltd | Vaccine |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US6989892B2 (en) * | 2004-03-22 | 2006-01-24 | Fluke Corporation | Optical fiber propagation time measurement |
| CN102614510A (zh) * | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| KR20080043775A (ko) | 2005-07-11 | 2008-05-19 | 글로브이뮨 | 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물 |
| BRPI0715714A2 (pt) | 2006-08-25 | 2014-03-11 | Wyeth Corp | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente |
| AU2008214029B2 (en) | 2007-02-02 | 2014-01-30 | Globelmmune, Inc. | Methods for producing yeast-based vaccines |
| EP2134358A1 (en) | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
-
2005
- 2005-10-18 CN CN2012101052485A patent/CN102614510A/zh active Pending
- 2005-10-18 WO PCT/US2005/037499 patent/WO2006044923A2/en not_active Ceased
- 2005-10-18 EP EP12157168.1A patent/EP2460533A3/en not_active Withdrawn
- 2005-10-18 CA CA002584562A patent/CA2584562A1/en not_active Abandoned
- 2005-10-18 JP JP2007537026A patent/JP2008516610A/ja active Pending
- 2005-10-18 CN CN2005800434620A patent/CN101437964B/zh not_active Expired - Fee Related
- 2005-10-18 SG SG200906938-6A patent/SG156652A1/en unknown
- 2005-10-18 AU AU2005295317A patent/AU2005295317B2/en not_active Ceased
- 2005-10-18 MX MX2007004662A patent/MX2007004662A/es active IP Right Grant
- 2005-10-18 BR BRPI0516356-0A patent/BRPI0516356A/pt not_active IP Right Cessation
- 2005-10-18 KR KR1020077011275A patent/KR20070068460A/ko not_active Ceased
- 2005-10-18 EP EP05812919.8A patent/EP1809773B1/en not_active Expired - Lifetime
-
2006
- 2006-12-31 US US11/618,834 patent/US7632511B2/en not_active Expired - Fee Related
- 2006-12-31 US US11/618,833 patent/US7625569B2/en not_active Expired - Fee Related
-
2007
- 2007-04-17 IL IL182609A patent/IL182609A/en not_active IP Right Cessation
-
2008
- 2008-08-22 US US12/196,439 patent/US8007816B2/en not_active Expired - Lifetime
-
2009
- 2009-12-04 US US12/631,039 patent/US8388980B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 JP JP2011216827A patent/JP2012034700A/ja active Pending
-
2013
- 2013-01-08 US US13/736,368 patent/US8821892B2/en not_active Expired - Fee Related
- 2013-08-05 JP JP2013162490A patent/JP2014012679A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516610A5 (https=) | ||
| Failla et al. | Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins | |
| Bartenschlager et al. | Kinetic and structural analyses of hepatitis C virus polyprotein processing | |
| Leary et al. | Sequence and genomic organization of GBV‐C: A novel member of the Flaviviridae associated with human non‐A‐E hepatitis | |
| Mizushima et al. | Two hepatitis C virus glycoprotein E2 products with different C termini | |
| Lin et al. | A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro | |
| Bartenschlager et al. | Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation | |
| Major et al. | The molecular virology of hepatitis C | |
| Grakoui et al. | Expression and identification of hepatitis C virus polyprotein cleavage products | |
| Tautz et al. | Serine protease of pestiviruses: determination of cleavage sites | |
| Lin et al. | Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini | |
| Bartenschlager et al. | Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase | |
| Tautz et al. | NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease–cofactor interactions | |
| Ryan et al. | Virus-encoded proteinases of the Flaviviridae. | |
| Butkiewicz et al. | Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity | |
| Hirowatari et al. | Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector | |
| US20100278865A1 (en) | Production and use of epitope-tagged hepatitis c virus particle | |
| CN102016026B (zh) | 含有来自丙型肝炎病毒的嵌合基因的核酸 | |
| ES2273934T5 (es) | Antígeno del virus de la hepatitis no a, no b, métodos diagnósticos y vacunas. | |
| EP0763114B1 (en) | Hepatitis g virus and molecular cloning thereof | |
| Shimotohno | Hepatitis C virus as a causative agent of hepatocellular carcinoma | |
| Yen et al. | Cellular proteins specifically bind to the 5′-noncoding region of hepatitis C virus RNA | |
| JP3045778B2 (ja) | C型肝炎ウイルスプロテアーゼの不溶性凝集物をリフォールディングするための方法 | |
| Khudyakov et al. | Artificial mosaic protein containing antigenic epitopes of hepatitis E virus | |
| EP1993603B1 (en) | Hepatitis c virus non structural fusion protein |